Endo International PLC (ENDP.O)
ENDP.O on Nasdaq
6.95USD
30 Jan 2018
6.95USD
30 Jan 2018
Change (% chg)
$-0.24 (-3.34%)
$-0.24 (-3.34%)
Prev Close
$7.19
$7.19
Open
$7.04
$7.04
Day's High
$7.07
$7.07
Day's Low
$6.85
$6.85
Volume
4,809,311
4,809,311
Avg. Vol
5,927,684
5,927,684
52-wk High
$14.45
$14.45
52-wk Low
$5.77
$5.77
About
Endo International plc is a generics and specialty branded pharmaceutical company. The Company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals and International Pharmaceuticals. It has a portfolio of branded pharmaceuticals offered by its U.S. Branded Pharmaceuticals segment that... (more)
Overall
| Beta: | 0.29 |
| Market Cap(Mil.): | $1,605.62 |
| Shares Outstanding(Mil.): | 223.31 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| Industry | Sector | ||
|---|---|---|---|
| P/E (TTM): | -- | 34.64 | 18.41 |
| EPS (TTM): | -- | -- | -- |
| ROI: | -- | 14.81 | 35.52 |
| ROE: | -- | 16.36 | 17.20 |
Endo unit settles case ahead of first state court testosterone trial
Endo International's Auxilium unit on Tuesday settled a lawsuit over its testosterone replacement drug, just days before the case was set to go to trial in what would have been the first such legal proceeding at the Philadelphia Court of Common Pleas.
Endo unit cleared of liability in first testosterone replacement trial
NEW YORK A federal jury in Chicago said on Thursday that Endo International's Auxilium unit was not responsible for the heart attack a man suffered while using the company's testosterone replacement drug Testim.
Endo unit cleared of liability in first testosterone replacement trial
NEW YORK, Nov 16 A federal jury in Chicago said on Thursday that Endo International's Auxilium unit was not responsible for the heart attack a man suffered while using the company's testosterone replacement drug Testim.
Estimates